The need to identify robust markers to predict the response to endocrine therapy in ESR1-related tumors, such as breast cancer, has received increasing attention, because only 50–70% of patients with receptor-positive tumors (identified by high ESR1 expression) respond to this treatment. The gene discussed is ESR1; the disease is breast carcinoma.